This Week in Psychedelics

Plus Colorado voters pass a ballot initiative to expand psychedelic legalization; Beckley Psytech begins Phase I clinical trial on ELE-101.

November 11, 2022

This Week...

The big news this week was out of Colorado, where voters approved a ballot initiative that would legalize the possession of certain psychedelics and create psilocybin “healing centers.” Here’s more:

Beckley Psytech announced that the first participant has been dosed in its Phase I clinical trial of ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression.

The trial is a double-blind, randomized, placebo-controlled study designed to assess the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD), and subjective drug intensity (SDI) of single ascending intravenous doses of ELE-101 in up to 60 healthy adult participants. Full results of the study are expected in H1 2023, and blinded data will be used to help design the Phase II study, with initiation also planned for H1 2023. Check it out:

Did You Know?

Did you know that in ancient Peruvian rituals, human sacrifices ingested psychedelic substances? In a new analysis, researchers identified evidence of San Pedro cactus from a single hair plucked from the mummified skull of a human that was sacrificed. They also found evidence of ingested coca leaves and traces of Banisteriopsis caapi, which is the main compound in ayahuasca.

These findings were published in the Journal of Archeological Science, which you can read here: